



Futura Medical PLC

June 10 2019

Futura Medical on the rise as Liberum says newspaper article could spark interest in group's main ED product

Futura Medical PLC (LON:FUM) saw its shares shoot higher on Monday after 'house' broker Liberum Capital highlighted an article published in 'The Guardian' newspaper which could spark interest in the group's main product.

In a note to clients, the City broker's analysts pointed out that over the weekend the newspaper published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on the AIM-listed firm's MED2005 which is in a P3 study due to read-out by the end of the year.

READ: Futura Medical trial on track to deliver "major value inflection point" They said: "The article highlights the lack of clinical advances in ED over the past 20 years and the emerging opportunity for products that can address the shortcomings of the PDe-5 inhibitor class (Viagra) with MED2005 appearing to offer convenience and side-effect profile benefits."

The analysts concluded: "This will help to drive interest in what appears to be a very over-looked product in terms of its potential to address a very large market."

In afternoon trading, shares in Futura Medical were up 11.6% at 23.15p.

Price: 45.35p

Market Cap: 9

Share Information

Code: FUM

Listing: AIM

52 week	High	Low
	47.8p	5.65p

Sector: Pharma & Biotech

Website:

<https://www.futuramedical.com/index.asp>

Company Synopsis:

Futura Medical is an innovative R&D company with a pipeline of products in late stage development. We are experts in transdermal delivery and have developed an advanced proprietary transdermal technology, DermaSys®. Our lead product MED2005, is a breakthrough topical treatment for erectile dysfunction currently in Phase 3 clinical trial with potential peak sales of \$1bn1.

Author:

Jon Hopkins

+44(0)1202770386

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content



published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.